Pandion is a clinical-stage drugmaker based in Massachusetts that specializes in autoimmune disease drugs.
Pandion’s shares increased 132 percent Feb. 25 after the announcement, Business Insider reported.
The deal is expected to close in the first half of 2021.
Read the full news release here.
More articles on pharmacy:
Moderna CMO to leave the company
CVS expands COVID-19 vaccinations to 17 states
Moderna, Pfizer testing ways to boost COVID-19 vaccines against variants
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
